NCT01432717View on ClinicalTrials.gov

Study of ACE-536 in Healthy Postmenopausal Women

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

October 31, 2012

Conditions
Anemia
Interventions
BIOLOGICAL

ACE-536

Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.

OTHER

Placebo

Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.

Trial Locations (1)

Unknown

Acceleron Investigative Site, Tempe

All Listed Sponsors
lead

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

INDUSTRY

NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women | Biotech Hunter | Biotech Hunter